A Study to Assess Safety and Tolerability of Single Oral Doses of BMS-986177 in Patients With ESRD Treated With Chronic Hemodialysis
Phase of Trial: Phase I/II
Latest Information Update: 08 Sep 2017
At a glance
- Drugs BMS 986177 (Primary) ; Enoxaparin sodium; Heparin
- Indications Thrombosis
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 05 Jul 2017 Planned End Date changed from 14 Feb 2018 to 25 Oct 2017.
- 05 Jul 2017 Planned primary completion date changed from 13 Feb 2018 to 24 Oct 2017.
- 05 Jul 2017 Status changed from not yet recruiting to recruiting.